Why does Jim Cramer think Kimberly-Clark is a good opportunity?

He believes the merger with Kenvue will create shareholder value, and it's a defensive play in consumer staples.

What is Johnson & Johnson's role in the Kimberly-Clark and Kenvue deal?

Kenvue is the spin-off from Johnson & Johnson (JNJ), and it is now merging with Kimberly-Clark.

Jim Cramer Likes Kimberly-Clark for Its Kenvue Merger

Jim Cramer highlighted Kimberly-Clark (KMB) on Mad Money, calling it an interesting play due to its merger with Kenvue, the Johnson & Johnson spin-off.

June 5, 2026

2 min read

Source: Insider Monkey

Jim Cramer, host of CNBC's Mad Money, mentioned Kimberly-Clark Corporation (NASDAQ: KMB) during his segment on overlooked opportunities. He described it as an "odd one," saying: "We need some staples. I've got an odd one. How about a stock I haven't talked about at all? How about Kimberly-Clark? Here's a premier Kleenex..."

Recommendation Details

Cramer pointed to Kimberly-Clark's merger with Kenvue, the consumer health company spun off from Johnson & Johnson (NYSE: JNJ), as a key catalyst. Kimberly-Clark is known for its tissue and hygiene products, while Kenvue owns strong consumer brands. Cramer believes the deal could unlock shareholder value.

Context

The recommendation comes amid market volatility, with investors seeking defensive plays in consumer staples. Kimberly-Clark offers a solid dividend yield, adding to its appeal.

What This Means for Investors

While Cramer's endorsement may draw attention, investors should conduct their own due diligence on the merger details and valuation before making decisions.

Frequently Asked Questions

Jim Cramer recommended Kimberly-Clark (KMB) on Mad Money, citing its merger with Kenvue.

Found this useful? Share it

This article was rewritten in Wrqti's editorial style based on information from the original source above. Content is informational only — not investment advice.